Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Clinical Trial ID NCT01721876

Rank	Title	Journal	Year	PubWeight™‹?›
1	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.	Leukemia	2014	1.28
2	Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.	Transl Oncol	2015	1.12
3	Novel drugs for older patients with acute myeloid leukemia.	Leukemia	2014	0.99
4	New drugs in acute myeloid leukemia.	Ann Oncol	2016	0.88
5	Update on rational targeted therapy in AML.	Blood Rev	2016	0.85
6	New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.	Clin Cancer Res	2014	0.83
7	Targeting polo-like kinase 1 in acute myeloid leukemia.	Ther Adv Hematol	2015	0.82
8	The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.	Risk Manag Healthc Policy	2015	0.78
9	Volasertib for AML: clinical use and patient consideration.	Onco Targets Ther	2015	0.77
10	Rational Combinations of Targeted Agents in AML.	J Clin Med	2015	0.76
11	Acute Myeloid Leukemia in the Elderly Patient: New Strategies.	Rare Cancers Ther	2015	0.75
12	Maintaining Genome Stability in Defiance of Mitotic DNA Damage.	Front Genet	2016	0.75
13	Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.	Front Oncol	2015	0.75
14	Acute myeloid leukemia: advancing clinical trials and promising therapeutics.	Expert Rev Hematol	2016	0.75